Key Highlights
SGLT2 inhibitor therapy does not increase 1-year amputation risk in patients with diabetic foot ulcers, challenging prior concerns about potential harm. Patients receiving SGLT2 inhibitors demonstrated a dramatic reduction in 1-year mortality (1.1% vs 9.2%, P = 0.009), representing an 88% relative reduction in death risk. Wound healing time was significantly shorter in the SGLT2 inhibitor group, with a mean difference of 44 days (136.5 vs 181.2 days, P = 0.04). The findings provide important real-world evidence for the safety profile of these agents in a high-risk population.
